micro-community-banner
  • Saved

3yr
Immune checkpoint inhibitor sintilimab-induced lethal... : Medicine

Immune checkpoint inhibitor sintilimab-induced lethal... : Medicine

Source : https://journals.lww.com/md-journal/Fulltext/2023/04140/Immune_checkpoint_inhibitor_sintilimab_induced.30.aspx

al, have been increasing reported. Patient concerns: A 45-year-old thymoma patient was admitted to our hospital after receiving anti-programmed cell death-1 treatment with sintilimab 14 days later, accompanied by abdominal...

Lessons: The case aims to raise awareness of immune-mediated cardiotoxicity and bring thoughts to the prospects of immunotherapy in thymoma.

  • Saved

3yr
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder

Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder

Source : https://n.neurology.org/content/100/13/e1418

Background and Objectives Studies on tumefactive brain lesions in myelin oligodendrocyte glycoprotein-immunoglobulin G (IgG)-associated disease (MOGAD) are lacking. We sought to characterize the frequency clinical, laboratory, and MRI features of...

Discussion: Tumefactive lesions are frequent in MOGAD but not associated with a worse prognosis. The clinical, MRI, and CSF attributes of tumefactive MOGAD differ from those of tumefactive MS and are more similar to those of tumefactive AQP4+NMOSD with the exception of lesion resolution, which favors MOGAD.

  • Saved

3yr
A Preview of the American Academy of Neurology: AAN 2023 Annual Meeting

The American Academy of Neurology (AAN) is hosting its 75th annual meeting in Boston from April 22 to 27, 2023. Attendees have options for in-person or virtual sessions.

Virtual attendees can explore an online poster gallery and will have access to AAN Rewind to view missed sessions within 48 hours of their conclusion. In-person attendees will receive one complimentary ticket to the 75th Anniversary Celebration on Sunday, April 23, and can attend their choice of eight hands-on skills workshops.

Click above for an exclusive preview of the event. 

  • Saved

3yr
Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis - PubMed

Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37013835/

Treatment of acute exacerbations and refractory myasthenia gravis (MG) remains challenging despite advances in immunotherapy. Frequent use of plasmapheresis and immunoglobulins are associated with adverse events and strain on resources....

Conclusions/Relevance: Efgartigimod is a well-tolerated drug that inhibits IgG autoantibodies with minor side effects such as headache and upper respiratory (lung) and urinary tract infections. Efgartigimod may be a potential treatment strategy in patients with MG. Studies are now being carried out to determine how efgartigimod works in a...

  • Saved

3yr
JPMA - Journal Of Pakistan Medical Association

JPMA - Journal Of Pakistan Medical Association

Source : https://jpma.org.pk/article-details/11643?article_id=11643

Kashaf Waqar ( Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan, Pakistan. ) Anika Zainab ( Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan,...

Relevance: Efgartigimod was FDA approved for treating myasthenia gravis on 17th December 2021.